Amazon adds Ozempic pill to same-day prescription drug kiosks
Amazon is building something it hopes will become the easiest place to pick up drugs you can't get at a regular pharmacy.
The company announced May 7 — according to Reuters and CNBC — that it is stocking Novo Nordisk's Ozempic pills — the oral form of the blockbuster GLP-1 medication, a class of drugs used to treat diabetes and obesity — at its pharmacy kiosks, offering same-day delivery to roughly 3,000 locations and scaling to 4,500 by the end of the year. Wegovy pills, Novo Nordisk's separate obesity formulation, are already in five California kiosks near Amazon's One Medical clinics. The cash price is $149 a month, dropping to $25 with insurance coverage.
The catch — and the reason this matters beyond the obvious Amazon-contains-Amazon angle — is that the injectable version of Ozempic isn't in those kiosks. According to Reuters, Amazon does not stock the injectables in kiosks because they need refrigeration; the pills do not. That formulation difference is what let Amazon announce same-day delivery today instead of waiting another year.
Endpoints News first reported the Amazon announcement. Amazon has been in the GLP-1 delivery business since 2021, when it first started shipping the medications through Amazon Pharmacy. But pharmacy delivery at scale has always run into the same wall: the last hundred feet. Mail-order works for daily pills that sit at room temperature. It works less well for medications patients need urgently, or for people who don't want a package left on a porch. Kiosks are Amazon's answer to that problem, and the company says its $4 billion 2025 investment is aimed at tripling delivery options across its broader network — not specifically at pharmacy or GLP-1 drugs, and Amazon declined to specify what portion targets the kiosk channel. The five kiosks currently stocking GLP-1 pills are near its One Medical clinics in California, making them a pilot, not a footprint.
To date, Amazon Pharmacy customers have saved over $200 million through an automatic manufacturer coupon program, according to Amazon's corporate blog. Whether that message survives contact with the reality that most Americans still need a prescription to access GLP-1s — and that shortages of the oral form have been intermittent at best — is the open question the announcement doesn't answer.
Novo Nordisk is not the only company with an oral GLP-1 on the market, and it is not the only company Amazon could stock at its kiosks. The architecture being built here is designed to be drug-agnostic: a network of temperature-appropriate pickup points that any manufacturer can tap into. The strategic prize is not the Ozempic customer specifically. It is the pharmacy supply chain relationship that precedes whichever drug wins the next wave of metabolic disease treatment. Whoever controls that last-mile infrastructure sets the terms for which drugs get to patients, and at what price.
The GLP-1 market is large and getting larger. Novo Nordisk reported Diabetes and Obesity care sales of roughly 289.5 billion Danish kroner in 2025, according to the company's own full-year results — a figure that reflects years of supply constraints finally easing as oral formulations expand and manufacturing scales. The bottleneck is shifting from production to distribution. Amazon is making a bet that the next fight will be physical, not pharmaceutical. The Ozempic pill is the opening move.
If the kiosk-and-delivery model scales for oral GLP-1s, industry observers expect every room-temperature chronic disease drug to become a candidate for the same channel — though no manufacturer has announced a formal partnership and it remains unclear how quickly the model could replicate.
Wegovy pills remain available at only a handful of California locations. The broader kiosk network is coming. The prescription question — who gets access, and at what cost — is a problem Amazon has not solved. It has only moved it to a more convenient address.